Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Specialty Networks Research.
With
Eli Lilly and Company
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥21 years at the time of enrollment
Confirmed diagnosis of ulcerative colitis (UC) or Crohn's disease (CD)
Eligible for treatment with biologic therapy for IBD, defined as failure of prior conventional therapy and/or prior biologic therapy (excluding IL-23p19 antagonists)
No prior exposure to mirikizumab and no contraindications to mirikizumab
Ability to provide informed consent
Willingness to comply with study procedures and follow-up requirements
You may not be if
Prior exposure to IL-23p19 antagonists (e.g., mirikizumab, risankizumab, guselkumab)
Prior exposure to small molecule targeted therapies for IBD (e.g., JAK inhibitors or S1P receptor modulators)
Participation in an interventional clinical trial within 90 days prior to enrollment
History of extensive colorectal resection, including:
Total proctocolectomy (for UC), or
Surgical removal of two or more intestinal segments (for CD)
Any condition that, in the investigator's judgment, may compromise patient safety, data integrity, or ability to participate in the study
